Serum lipids were serially determined in 11 patients receiving pentolinium therapy to evaluate changes secondary to blood pressure effects. Substantial reduction in total Cholesterol was observed, which in some cases was independent of the hypotensive effect of the drug. Fat absorption, studied in 6 patients, revealed diminished postprandial lipemia in each as' compared to placebo determinations. However, few patients showed appreciable weight change during a year of therapy. The evidence suggests that the serum lipid changes seeondary to pentolinium administration are due to a qualitative change in fat absorption.
THE association of arterial hypertension
and an increased incidence of atherosclerosis has been previously noted.1-3 In studies of atherosclerotic patients assays of the serum lipids have been utilized as an indicator of the status of the disease. These measurements usually include serum cholesterol, phospholipid, and total lipid as well as the determination of the distribution of lipid in the lipoprotein complex by ultracentrifugation, zone electrophoresis, or chemical fractionation. According to Page and associates,4 patients with uncomplicated essential hypertension are free of plasma lipid abnormalities. On the other hand, Gofman and associ-ates2 have pointed out that the great majority of patients with sustained hypertension have significantly increased serum levels of Sf 10-20 molecules. More marked derangement of the serum lipids might be predicted in a group of patients with long standing severe hypertension presumably with a greater incidence of atherosclerosis. Were such the case, it would be pertinent to determine if measurable changes in the serum lipids are demonstrable during treatment of the hypertension by the currently available hypotensive agents.
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Dr. Orvis was a Fellow in Cardiovascular Disease, the Washington Heart Association 1955-1956. 176 In this study, serum cholesterol was serially determined in a group of 11 middle-aged patients with severe hypertension during treatment with pentolinium and reserpine and during control periods.
The investigation was extended to include a study of fat absorption when it became evident that a substantial drop in serum cholesterol occurred in many of the patients during treatment. In hypertensive patients receiving hydralazine and hexamethonium (Ilyphex), Schroeder5 had previously noted a tendency for the serum cholesterol to decrease.
It is the purpose of this paper to report the changes observed in serum lipids incident to pentolinium therapy. Evidence for altered lipid absorption during therapy was obtained in each of the 6 patients so studied. The possible relationship of this finding to the changes in serum lipids during therapy is discussed.
MATERIAL AND METHOD The patients for this investigation were selected from the Hypertension Clinic, The George Washington University Hospital. Criteria for admission to the study included age 55 or under, sustained diastolic pressure of 110 or greater, and unsuccessful prior treatment with reserpine alone or in combination with hydralazine.
Evaluation prior to therapy included a chest film, an electrocardiogram, the phenolsulfonphthalein test, and determination of the blood urea nitrogen. All of the patients had either electrocardiographic or roentgenologic evidence of left ventricular hypertrophy and 9 of the 11 patients had both. Impaired renal function was indicated in all patients by reduced 15-minute excretion of phenolsulfonphthalein, but in none was there elevation of the blood urea nitrogen. Each of the patients received reserpine, in doses of 0.25 to 0.75 mg. daily, beginning at least 1 month before administration of pentolinium (Ansolysen).* Upon initiation of the latter medication, patients were seen weekly or biweekly until the desired pressure response was obtained. When symptoms of postural hypotension appeared, standing blood pressures were recorded in the clinic every half hour for 3 hours after the midday dose. This procedure was usually satisfactory in establishing the maximum hypotensive effect of the drug. Severe constipation occurred in 6 patients for which 15 mg. of prostigmine bromide or 5 mg. of pilocarpine nitrate was administered daily throughout the study. Patients' diets were not altered and none had been on a low-fat diet. Only 1 subject (E. H.) lost weight during the year of therapy and in this patient there was a complicating illness.
Congestive heart failure was severe (requiring diuretic therapy) in 1 patient (L. S.). Significant fluid retention was not encountered in the other patients, so that we were able to maintain a constant therapeutic regimen during the investigation.
One year after initiation of therapy 6 patients with the least cardiorenal involvement were given a lactose placebo for 6 weeks in place of the pentolinium. Reserpine, parasympathomimetic drugs, and all other medications were continued. Thus, *Kindly supplied by Wyeth Laboratories.
it was thought that any alteration in serum lipids could be ascribed to withdrawal of the pentolinium.
Blood samples were obtained in the fasting state at the onset of the study and at intervals thereafter. During the placebo period, fasting specimens were obtained biweekly. Serum cholesterol determinations were done in the hospital laboratory by the method of Bloor.6 An oral fat-tolerance test was done just prior to and in the third week of the placebo period. The oral fat-tolerance method utilizes changes in serum turbidity after a standard fat meal as a measurement of postprandial lipemia. The test was performed by the method of Waldow and associates.7
RESULTS
Pentolinium dosage and average control and treatment blood pressures are presented in table 1. It may be seen that a substantial reduction in average blood pressure was achieved in 6 of the 11 patients. Five of these 6 were in the group given the placebo and in each the blood pressure rose to approximate the pretreatment level.
The serum cholesterol for each individual in relation to the periods of study is given in table 1. It is apparent that the control cholesterol exceeded 250 mg. per cent in 10 of the 11 patients, and, that several patients exhibited a marked drop, the reduction being CoincidenAt witlh p)eniitol iniuimi administration there was a sulbstantial drop in serum cholesterol ini 9 of 11 patients. Schroedeer5 has re-1orted similar changes ill serum cholesterol with the admi 11 istration of hvdralazin e and lhexamietlhoiumiii. It is possible that the re-sJonsible conlimion factor is the aiiglioniblocking agenit. The chan-res ill cholesterol were seeni ill 3 of our l)atients ill the absenice of ally lowering of 1)loo0( pressure. Th is would seem to iudicate that the drop iii ('holesterol is not due primnarily to the decline ill arterial blood pressure. Such all inference is further supported by our failure to demonistrate the lly)ocholesteremie effect ill patienlts reimdered hypotensive by reserpinie alonie or inl a patient relieve(d of hypertension by siirgelry for ('oaretatiol of the aorta."
It is siu(geted that the observed lipid (.lalages may be due ill part to altered lipi(l absorption, since postprandial lipemia after fat tolerance testing was invariably lower dur- .1830
Optical density of sera before and at 3 and 5 hours after ingestion of 40 Gm. of fat. Test performed approximately 1 year after initiation of therapy and in the third week of the placebo period. iligr )(,ittoliniim therapy ill tile 6 patientts so studied. The chanlge in lipid absorption would seem to be in the direction of a qualitative alteration rather than reduced absorption. since only 1 of the 11 subjects lost weight during treatment. An additional factor may b)e the decrease in intestinal motilitv accompanyin g ganglionie-b)lo(k.ade tlherap-. It has 'been repeatedly shown that the hydrolysis of triglyNcerides in the smiall intestine is incoimil)lete during the usual absorptive period.9' 10 Ilncreased transit time of food in the small intestine mi(rhlt allow more complete fat diges-tionI prior to absorption. While this could 1)e the mechanism by -which )eiitoliiinlll lowers lostprandial lipemiia, altered intestinal motility does not readily explain the hypo-( hiolesteremiic effect. Further studv is illdicatedl to clarify this point.
Fasting serum chliolesterol was determni ned iii 11 patients with severe arterial hypertens-ion before an(d at intervals duringr treatment, 1 with pentolinium. In 9 of the 11 patienlts there was a decrease in cholesterol averaging, 57.8 ulig. per cent for the group, after therapy.
These findings were further sul)stanitiated iii 6 of these patients in that serimn cholesterol levels rose durinig a period of placebo treatment. The lipid changes observed appeared to be independent of the hypoteuusive effect of leiltolinillm.
An oral fat-tolerance test revealed lower1 lostpralldial lipemia in 6 subjects durinr pelntolinium as comparecl to placebo treatnient. This finding was iulterl)rete(l as evidencre for altered lipid absorption or digestioli incident to peintoliiiiuini therapy. It is sug-Cested that the alteration is qualitative ini nature, since b)ody weiglt remainied stable over a year of treatment ini most of the patients. ADDENDUM Since the completion of this paper, a similar fall of serum cholesterol has been observed in patients tie eted with mecamylamine or chlorisondaiiiiine; the decrease averaged 26 per cent of control values ini a group of 10 patients. It was an not(d that the greater effect was in I)atients with highei. initial cholesterol values. SUMMARIO IN INTERIANGUA lie cholesterol del sero esseva determinate ini stato jejun in 11 patielites eon sever hypertenlsiomi arterial ante e periodicamente duranlte le tractamento con pentolinium. Ini 9 del 11 p)atielntes, Un reduction de cholesterol esseva notate post le traetamento, amontante a Un valor inedie pro le gruppo integre de 57,8 pro cento. Iste constatation esseva corroborate additionalineiite in tanto que le nivellos del cholesterol seral inontava ini 6 dcel mesme patientes durante ull periodo de tractamento a medieation fietitie. lie alterationes lipidic ol)servate e seva apparelltemente independente del effecto hypotensive de pentolinium.
Un test de tolerantia de grassia oral revelava 1)phis basse nivellos postprandial de lipemia in 6 subjectos durante tractainento a pentolinilun q ue (durante tractamiento a me(licationl fictitie. Iste constatation esseva interpretate (o01o prova de uin alterate absorption o diges-t1iOl de lipido in association Con le therapia a l)eltolinuium. Es exprinfite le opinion que le alteration es de (character qualitative, pro(ue le pesos corporee remaneva stabile in Ic majoritate del patientes in le eurso de un ainno de therapia.
